印度新冠确诊连续第五天破全球纪录 惟孟买指数回升1.4%
印度新增单日确诊病例接近35.3万,连续第五天刷新全球单日确诊纪录。不过,印度孟买指数扭转上周五跌势,今天曾反弹1.6%至48,667,现造48,552,回升1.4%,仅次於区内表现最强劲的台湾,台湾加权指数高收17,572再破顶,续涨近1.6%。
根据印度卫生部门今天(26日)通报,於过去24小时,印度新增新冠确诊宗病例352,991人,连续第五天刷新全球单日确诊纪录,累计确诊超过1,731万人;新增死亡病例2,812例,累计达195,123例。当地疫情失控,总理莫迪政府被批评防疫松懈,容许大型宗教和政治聚会,在之前疫情缓和时,也没有制定改善医疗体系的计划。由於印度疫情持续恶化,导致医疗系统濒临崩溃,多国伸出援手,美国指将立即提供制造阿斯利康疫苗的原材料、呼吸机等医疗设备及保护装备,也会考虑是否直接向印度提供阿斯利康疫苗。至於英国正运送呼吸机和氧气机等合共600件医疗设备,预计首批将於周二抵运当地;法德两国也将於未来数天向印度分别提供呼吸仪器及氧气等医疗物资。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.